2,3-dihydro-N-hydroxy-6-[(4-methoxy-1-piperidinyl)sulfonyl]-1,4-benzodioxin-5-carboxamide | 308385-64-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 2,3-dihydro-N-hydroxy-6-[(4-methoxy-1-piperidinyl)sulfonyl]-1,4-benzodioxin-5-carboxamide
• 英文别名: N-hydroxy-6-(4-methoxypiperidin-1-yl)sulfonyl-2,3-dihydro-1,4-benzodioxine-5-carboxamide
• CAS: 308385-64-0
• 化学式: C₁₅H₂₀N₂O₇S
• 分子量: 372.399
• InChiKey: IYJRQFZOMZHNEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  123
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
  申请人：——

  公开号：US20030073845A1

  公开（公告）日：2003-04-17

  This invention is directed to sulfonyl aromatic hydroxamic acid compounds and salts thereof that, inter alia, inhibit matrix metalloprotease (MMP) activity and/or aggrecanase activity. In some particularly preferred embodiments, the compound corresponds in structure to one of the following formulas: 1 wherein W 2 , the R groups, and —A—R—E—Y are described in more detail in Applicants' specification. This invention also is directed to a process that comprises administering such a compound or pharmaceutically acceptable salt thereof to a host animal having a condition associated with MMP activity.

  本发明涉及磺酰基芳基羟肟酸化合物及其盐，这些化合物在抑制基质金属蛋白酶（MMP）活性和/或聚集素酶活性方面具有作用。在一些特别优选的实施方式中，该化合物的结构符合以下公式之一：其中W2、R基团和—A—R—E—Y在申请人的说明书中有更详细的描述。本发明还涉及一种过程，该过程包括向患有与MMP活性相关的病况的宿主动物施用这种化合物或其药用可接受盐。
• USE OF SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACIDS AND DERIVATIVES THEREOF AS AGGRECANASE INHIBITORS
  申请人：Pharmacia Corporation

  公开号：EP1406602A2

  公开（公告）日：2004-04-14
• SULPHONYL ARYL HYDROXAMATES AND THEIR USE AS MMP INHIBITORS
  申请人：Pharmacia Corporation

  公开号：EP1406626A2

  公开（公告）日：2004-04-14
• US6696449B2
  申请人：——

  公开号：US6696449B2

  公开（公告）日：2004-02-24
• US6683078B2
  申请人：——

  公开号：US6683078B2

  公开（公告）日：2004-01-27